About idorsia ltd. - IDRSF
Idorsia Ltd. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of medicines for medical needs. It operates through the following geographical segments: Switzerland, United States, Japan, and EUCAN. The company was founded on March 3, 2017 and is headquartered in Allschwil, Switzerland.
IDRSF At a Glance
Idorsia Ltd.
Hegenheimermattweg 91
Allschwil, Basel-Landschaft (Basle Country) 4123
| Phone | 41-58-844-10-10 | Revenue | 266.11M | |
| Industry | Pharmaceuticals: Major | Net Income | -134,860,753.33 | |
| Sector | Health Technology | 2025 Sales Growth | 108.3% | |
| Fiscal Year-end | 12 / 2026 | Employees | N/A | |
| View SEC Filings |
IDRSF Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 4.333 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | 10.277 |
| Total Debt to Enterprise Value | 0.619 |
IDRSF Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | N/A |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
IDRSF Liquidity
| Current Ratio | N/A |
| Quick Ratio | N/A |
| Cash Ratio | N/A |
IDRSF Profitability
| Gross Margin | N/A |
| Operating Margin | 221.267 |
| Pretax Margin | N/A |
| Net Margin | -50.679 |
| Return on Assets | N/A |
| Return on Equity | N/A |
| Return on Total Capital | N/A |
| Return on Invested Capital | N/A |
IDRSF Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |